Avidity Biosciences Inc. is on the brink of a potential takeover by pharmaceutical giant Novartis, a move that could revolutionize the treatment of serious diseases and transform the biotech industry.

Avidity Biosciences Inc navigates market volatility in the biotech sector, where innovative therapeutics and regulatory hurdles pose both opportunities and challenges for the company’s future success.

Avidity Biosciences Inc. will participate in an upcoming investor conference to discuss its strategic initiatives and advancements in oligonucleotide therapeutics.